Business Context and Reporting Period
Company: Inventiva S.A.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: October 15, 2024
Context: The filing announces a multi-tranche private placement transaction and an amendment to an existing collaboration agreement. Inventiva is a clinical-stage biopharmaceutical company with no approved products or historical product revenues.
Key Financial Metrics and Capital Structure
Transaction Overview (Private Placement):
- Tranche 1 (T1): Issuance of 34,600,507 ordinary shares and 35,399,481 pre-funded warrants.
- Gross Proceeds: €94.1 million (Net proceeds: €86.6 million).
- Subscription Price: €1.35 per share (€1.34 for pre-funded warrants).
- Expected Closing: October 17, 2024.
- Tranche 1bis (T1bis): Issuance of 7,872,064 ordinary shares and 8,053,847 pre-funded warrants.
- Gross Proceeds: €21.4 million.
- Condition: Subject to shareholder approval by December 16, 2024.
- Tranche 2 (T2/ABSAs): Issuance of shares with attached warrants (T3 BSAs).
- Gross Proceeds: €116 million.
- Condition: Subject to shareholder approval and pricing mechanics.
- Tranche 3 (T3 BSAs): Warrants exercisable upon a triggering event.
- Maximum Proceeds: €116 million (upon full exercise).
- Exercise Price: €1.50 per share.
Collaboration Amendment (CTTQ):
- Partner: Chia Tai Tianqing Pharmaceutical Group, Co., LTD.
- Upfront/Milestone Payments: Up to $30 million payable upon completion of fundraising tranches and positive Phase 3 topline data.
- Royalty Adjustment: Royalty percentage on incremental annual net sales reduced to low single digits.
Use of Proceeds:
- 85%: Clinical program for lanifibranor (NATiV3) for MASH treatment and potential New Drug Application (NDA) submission.
- 15%: General corporate purposes.
- Future Tranches: Funding continuation of NATiV3, initiation of Phase 3 trial in compensated cirrhosis, and pre-commercialization activities.
Other Metrics:
- Revenue/Profit/Cash Flow: The filing text does not provide specific revenue, profit, or cash flow figures for the reporting period. The company is described as having incurred significant losses since inception with no product revenues.
- Debt/Liquidity: Specific debt levels and current liquidity balances are not disclosed in this filing.
Material Changes and Corporate Actions
Board Composition Changes:
- Appointment of Mark Pruzanski, M.D., and Srinivas Akkaraju, M.D., Ph.D., to the Board of Directors.
- Dr. Pruzanski appointed as Chairman of the Board.
- Agreement to nominate up to four additional board members proposed by investors, replacing existing members (excluding Frédéric Cren, Dr. Pruzanski, and Dr. Akkaraju).
Contractual Changes:
- Amendment to the CTTQ License Agreement linking milestone payments to the success of the current equity raise and clinical data.
Outlook, Risks, and Contingencies
Outlook and Guidance:
- Clinical Timeline: NATiV3 topline results scheduled for the second half of 2026.
- Capital Needs: The company requires additional capital to finance operations; failure to secure funding could force curtailment of programs.
Risks and Contingencies:
- Transaction Conditions: Proceeds from T1bis, ABSAs, and T3 BSAs are contingent on shareholder approval, satisfaction of conditions precedent, and investor exercise of warrants. Total proceeds may be lower than expected.
- Clinical Risks: Potential impact of a previously announced Suspected Unexpected Serious Adverse Reaction (SUSAR) on enrollment and trial results.
- Regulatory Risks: No guarantee of regulatory approval for lanifibranor or that clinical trials will support product claims.
- Geopolitical Risks: Potential adverse effects from conflicts (Russia-Ukraine, Israel-Hamas), sanctions, and macroeconomic conditions on trial initiation and completion.
- Going Concern: As a clinical-stage company with no revenue, the company faces risks regarding its ability to continue as a going concern without further financing.
Key Facts for Investor Verification
- Closing Status: Verify the actual closing date and final proceeds of the T1 tranche (expected October 17, 2024).
- Shareholder Approval: Monitor the outcome of the General Meeting (by December 16, 2024) required for T1bis and ABSA tranches.
- Warrant Exercise: Track the occurrence of the "triggering event" required to make T3 BSAs exercisable.
- Clinical Data: Review updates on the NATiV3 trial, specifically regarding the impact of the SUSAR on enrollment and safety profiles.
- Board Composition: Confirm the final composition of the Board of Directors following the appointment of new members and investor nominees.
- CTTQ Milestones: Verify the specific criteria and timing for the $30 million in potential milestone payments from CTTQ.